Check out the timestamps below to help you navigate through the many topics we discussed.
On This Episode:
This week, we’re shining a spotlight on Ciprofol, a cutting-edge intravenous anesthetic that has been making headlines in both clinical research and operating rooms worldwide.
With its innovative formulation and promising safety profile, Ciprofol is poised to transform the landscape of anesthetic practice. Join us as we explore how this new drug compares to established agents like propofol and what it could mean for the future of procedural sedation and anesthesia.
Ciprofol’s development is a testament to the progress in anesthetic pharmacology, addressing long-standing challenges such as pain on injection, adverse cardiovascular effects, and variability in patient response. Recent studies have highlighted its potential to offer smoother induction, better hemodynamic stability, and fewer complications, making it an attractive option for both routine and high-risk procedures. In this episode, we’ll dissect the science behind Ciprofol, examining its pharmacokinetics, clinical applications, and the data from key trials that support its use.
Here’s some of what we discuss in this episode:
- What is Ciprofol, and why are nurse anesthetists buzzing about it?
- The reduction in dosage isn’t just about using less drug—it has ripple effects.
- What about its pharmacokinetics? Does it have the same quick onset and recovery profile that we’ve come to rely on with Propofol?
- How does Ciprofol stack up when it comes to adverse events?
- We dissect the study—a randomized, double-blind trial conducted in China.
- Is Ciprofol the future?
Important Links:
"This drug represents an exciting alternative to opioids and acute pain management."
- Garry & Terry
Reference
Kingwell, K. (2025). NaV1.8 inhibitor poised to provide opioid-free pain relief. Nature Reviews. Drug Discovery, 24(1), 3–5. https://doi.org/10.1038/d41573-024-00203-3
Mullard, A. (2024). Vertex’s non-opioid painkiller passes phase III tests. Nature Reviews. Drug Discovery, 23(3), 162–162. https://doi.org/10.1038/d41573-024-00029-z
Oliver, B., Devitt, C., Park, G., Razak, A., Liu, S. M., & Bergese, S. D. (2025). Drugs in Development to Manage Acute Pain: Drugs in Development to Manage Acute Pain. Drugs (New York, N.Y.), 85(1), 11–19. https://doi.org/10.1007/s40265-024-02118-0
Osteen, J. D., Immani, S., Tapley, T. L., Indersmitten, T., Hurst, N. W., Healey, T., Aertgeerts, K., Negulescu, P. A., & Lechner, S. M. (2025). Pharmacology and Mechanism of Action of Suzetrigine, a Potent and Selective NaV1.8 Pain Signal Inhibitor for the Treatment of Moderate to Severe Pain. Pain and Therapy. https://doi.org/10.1007/s40122-024-00697-0
Vaelli, P., Fujita, A., Jo, S., Zhang, H.-X. B., Osorno, T., Ma, X., & Bean, B. P. (2024). State-Dependent Inhibition of Nav1.8 Sodium Channels by VX-150 and VX-548. Molecular Pharmacology, 106(6), 298–308. https://doi.org/10.1124/molpharm.124.000944
Vertex says FDA accepted suzetrigine new drug application. (2024, July 30). The Fly. https://link-gale.com.elibrary.mdanderson.org/apps/doc/A803124568/ITOF?u=txshracd2617&sid=bookmark-ITOF&xid=7ccbd478
